JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
01/12/22 - 18:30
2023 Annual Calendar of Corporate Events (288 KB)
09/11/22 - 7:04
DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance (134.99 KB)
07/11/22 - 7:12
DiaSorin commercializes molecular reagent for monkeypox virus (149 KB)
27/10/22 - 13:44
Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)
05/10/22 - 6:37
DiaSorin furthers its collaboration with BARDA for the LIAISON® NES (160.31 KB)
14/09/22 - 0:29
DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE (194.22 KB)
03/08/22 - 12:26
Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)
14/07/22 - 20:00
DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test (160.88 KB)
07/06/22 - 18:06
Execution of the project for the redefinition of the corporate structure of DiaSorin (286.22 KB)
20/05/22 - 7:08
DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay (106.16 KB)
09/05/22 - 7:02
DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™ (173.49 KB)
06/05/22 - 17:33
Update 2022 Annual Calendar of Corporate Events (285.68 KB)
06/05/22 - 16:45
Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)
02/05/22 - 12:55
Publication of the summary report of the votes cast (280.95 KB)
29/04/22 - 16:26
Shareholders' meeting 2022 (166.12 KB)
22/04/22 - 12:37
New proposal for resolution related to the remuneration of the Board of Statutory Auditors (281.82 KB)
13/04/22 - 16:43
DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative (282.86 KB)
08/04/22 - 19:13
Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution (291.36 KB)
08/04/22 - 9:53
Update annual calendar of corporate events 2022 (288.09 KB)
05/04/22 - 9:51
Notice pursuant to art. 144-octies, paga 2 of Consob Regulation No. 11971/1999 (309.07 KB)
04/04/22 - 18:12
Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l. (577.98 KB)
16/03/22 - 17:39
DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021 (404.69 KB)
08/03/22 - 7:13
DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel (105.47 KB)
13/01/22 - 7:24
DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant (486.67 KB)
21/12/18 - 11:30
DiaSorin launches 3 new primer pairs for use in molecular testing (438.25 KB)
04/12/18 - 8:00
DiaSorin's stocks listed in the FTSE MIB (464.63 KB)
19/11/18 - 15:00
DiaSorin launches Simplexa Group B Strep Direct molecular assay in the United States (435.43 KB)
07/11/18 - 13:00
DiaSorin Group reports growth in revenues and net profit in the first nine months of 2018 (961.72 KB)
17/10/18 - 11:51
DiaSorin launches Simplexa Group B Strep Direct molecular assay in the european market (147.78 KB)
12/10/18 - 11:47
DiaSorin launches Simplexa VZV Direct molecular assay in the european market (444.81 KB)
09/10/18 - 11:35
DiaSorin and Meridian enter into a strategic collaboration to sell Helicobacter pylori stool antigen test in the United States and in the United Kingdom (471.21 KB)
17/09/18 - 11:28
DiaSorin launches the new LIASON quantiFERON-TB Gold Plus assay as an aid for latent tuberculosis detection in partnership with Qiagen (753.85 KB)
07/08/18 - 8:45
Communication on total amount of voting rights (305.24 KB)
02/08/18 - 12:45
The Board of Directors approves the results for the first half of 2018 (883.1 KB)
27/07/18 - 12:00
DiaSorin launches Hepatitis Delta (HDV) test on LIAISON XL platform (735.03 KB)
03/07/18 - 18:30
Conclusion treasury shares buy-back plan (397.33 KB)
03/07/18 - 18:30
Annex 3F (treasury shares buy back July 2018) (6.59 KB)
03/07/18 - 18:30
Report treasury shares buy-back (287.99 KB)
03/07/18 - 18:30
Annex 3F (treasury shares buy back June 2018) (8.69 KB)
29/06/18 - 18:15
Weekly report treasury shares buy-back (290.62 KB)
22/06/18 - 20:30
Weekly report treasury shares buy-back (290.6 KB)
15/06/18 - 21:00
Weekly report treasury shares buy-back (290.62 KB)
12/06/18 - 14:15
DiaSorin introduces primer pair reagents for use in molecular testing: Anaplasma phagocytophilum, Ehrlichia e Babesia (445.17 KB)
08/06/18 - 23:15
Weekly report treasury shares buy-back (290.24 KB)
04/06/18 - 13:15
Annex 3F (treasury shares buy back May 2018) (8.54 KB)
01/06/18 - 20:15
Weekly report treasury shares buy-back (290.38 KB)
25/05/18 - 22:30
Weekly report treasury shares buy-back (289.97 KB)
19/05/18 - 1:45
Weekly report treasury shares buy-back (289.76 KB)
11/05/18 - 20:15
Weekly report treasury shares buy-back (290.77 KB)
08/05/18 - 14:30
The DiaSorin Group reports growth in revenues and profitability in the first quarter 2018 (832.84 KB)
03/05/18 - 20:15
Start up treasury shares buy-back plan (354.27 KB)
24/04/18 - 14:00
Annex 3F (treasury shares buy back) (7.77 KB)
23/04/18 - 18:30
Annual General Meeting 2018 (589.65 KB)
19/04/18 - 21:15
Conclusion treasury shares buy-back plan (397.59 KB)
19/04/18 - 21:00
Weekly report treasury shares buy-back (289.29 KB)
13/04/18 - 20:30
Weekly report treasury shares buy-back (290.07 KB)
06/04/18 - 19:45
Weekly report treasury shares buy-back (288.33 KB)
05/04/18 - 12:00
DiaSorin receives FDA clearance for the LIAISON BRAHMS PCT II GEN assay to detect severe bacterial infections (e.g. Sepsis) (737.88 KB)
04/04/18 - 20:00
Start up treasury shares buy-back plan (346.04 KB)
28/03/18 - 18:45
DiaSorin earns FDA clearence extending sample claims for Simplexa HSV 1 & 2 direct molecular test (442.69 KB)
07/03/18 - 15:30
DiaSorin: FY 2017 Results (1.14 MB)
30/01/18 - 11:45
DiaSorin signs an agreement with the Italian Tax Authority granting tax relief under the Italian Patent Box regime (574.68 KB)
08/01/18 - 9:00
QIAGEN and DiaSorin partner to offer fully automated tuberculosis detection with QuantiFERON-TB Gold Plus available on LIAISON analyzer systems (483.2 KB)
08/01/18 - 9:00